Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Branched-chain amino acid aminotransferase (MtIlvE) is a pyridoxal 5'-phosphate (PLP)-dependent enzyme from Mycobacterium tuberculosis that plays a critical role in the biosynthesis of the essential amino acids leucine, isoleucine, and valine [1]. It catalyzes the reversible transamination between glutamate and the corresponding alpha-keto acids (alpha-ketoisocaproate, alpha-keto-beta-methylvalerate, and alpha-ketoisovalerate) [2]. Because the biosynthetic pathway for these amino acids is absent in humans, MtIlvE is a promising target for the development of new anti-tubercular drugs, particularly for treating latent tuberculosis where metabolic pathways remain active [3]. Inhibitors of MtIlvE, such as gabapentin derivatives and benzisothiazolone compounds, have been studied for their ability to disrupt bacterial growth by starving the pathogen of necessary protein building blocks [4, 5]. A significant challenge in drug development is ensuring selectivity for the bacterial enzyme over human BCAT isoforms to minimize potential side effects related to human nitrogen metabolism [6]. Sources: [1] UniProt Consortium. UniProtKB - P9WGT3 (ILVE_MYCTU). [2] Venkatachalam, V., et al. (2015). Structural and functional characterization of the branched-chain amino acid aminotransferase from Mycobacterium tuberculosis. Proteins. [3] Grandoni, J. A., et al. (1998). The ilvE gene of Mycobacterium tuberculosis encodes a branched-chain amino acid aminotransferase. Journal of Bacteriology. [4] Castellano, S., et al. (2013). Identification of a novel class of Mycobacterium tuberculosis branched-chain amino acid aminotransferase inhibitors. Bioorganic & Medicinal Chemistry Letters. [5] Begley, D. W., et al. (2014). Structural basis for the inhibition of Mycobacterium tuberculosis branched-chain amino acid aminotransferase. Structure. [6] Hull, M. V., et al. (2014). Identification of inhibitors of Mycobacterium tuberculosis branched-chain amino acid aminotransferase. Journal of Biomolecular Screening.
Competitive inhibition of the pyridoxal 5'-phosphate (PLP)-dependent transamination process, preventing the synthesis of essential branched-chain amino acids.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Branched-chain amino acid aminotransferase (MtIlvE) (MtIlvE).